Mirati Therapeutics Inc (NASDAQ:MRTX) Shareholder Broadfin Capital Llc Lowered Position as Price Rose by $30.11 Million

May 17, 2018 - By Mary Markley

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Corporate LogoBig Money Sentiment increased to 2.21 in 2017 Q4. It has change of 1.04, from 2017Q3’s 1.17. The ratio increased due to MRTX positioning: 10 sold and 9 reduced. 27 funds bought positions and 15 increased positions. Investors holded 13.25 million in 2017Q3 but now own 17.76 million shares or 34.00% more. Moreover, Raymond James Svcs Inc has 0% invested in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Jennison Assocs Ltd Liability, a New York-based fund reported 487,599 shs. Royal Commercial Bank Of Canada invested in 0% or 99 shs. Vanguard holds 1.02 million shs. Ameriprise Financial invested in 18,678 shs. Wells Fargo And Co Mn holds 0% or 700 shs. D E Shaw & Incorporated holds 478,483 shs or 0.01% of its capital. Moreover, Federated Investors Pa has 0% invested in Mirati Therapeutics, Inc. (NASDAQ:MRTX) for 10,568 shs. 18,000 are held by Barclays Public Ltd Company. Citigroup reported 41,524 shs or 0% of all its holdings. Citadel Advsr Ltd Liability Corp holds 0% or 30,048 shs in its capital. Sg Americas Securities stated it has 45,430 shs. Architects owns 0% invested in Mirati Therapeutics, Inc. (NASDAQ:MRTX) for 1,050 shs. Alpine Glob Mngmt Ltd Liability Company invested in 0.08% or 18,472 shs. 25,224 were reported by Pdts Prns Ltd Com.

MRTX registered $4.97 million net activity with 0 insider buys and 7 insider sales since January 11, 2018. On Friday, March 9 Donadio Jamie A also sold $423,500 worth of Mirati Therapeutics, Inc. (NASDAQ:MRTX). Another trade for 51,810 shs valued at $1.45M was sold by BAUM CHARLES M.

In 2018Q1 SEC form is reported Kevin Kotler’s holdings in Mirati Therapeutics Inc (NASDAQ:MRTX) which was reduced by 41.01%. The company’s stock rose 63.01% while stock markets declined as Broadfin Capital Llc sold 1.00M shares. The health care company at the end of 2018Q1 was valued at $44.33 million. It’s down from 2.45 million at the end of the previous reported quarter. Now it had 1.44 million shares held by the hedge fund run by Kevin Kotler. Broadfin Capital Llc has risen its stake in La Jolla Pharmaceutical Co (NASDAQ:LJPC) and also increased its holding in Horizon Pharma Plc (NASDAQ:HZNP) by 2.26M shares in the quarter, for a total of 2.56 million shares.

Broadfin Capital is located in New York City and was founded by Kevin Kotler. Prior to Broadfin, Kotler could be found working for firms such as ING Barings, the Galleon Group, and ABN AMRO. Broadfin Capital Llc is a New York-based hedge fund that was founded by Kevin Kotler. It had more than $1.26 billion assets under management in December, 2014. Taken from Broadfin Capital latest Adv, the fund reported to have 10 full and part-time employees. Among which 5 performing investment advisory and research functions. The hedge fund had between 1-10 clients.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Ratings Coverage

In total 5 analysts cover Mirati Therapeutics (NASDAQ:MRTX). “Buy” rating has 5, “Sell” are 0, while 0 are “Hold”. (NASDAQ:MRTX) has 100% bullish analysts. 5 are the (NASDAQ:MRTX)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. The company rating was maintained by Citigroup on Monday, March 5. On Thursday, December 21 the stock of Mirati Therapeutics, Inc. (NASDAQ:MRTX) earned “Buy” rating by Cowen & Co. On Wednesday, April 25 H.C. Wainwright maintained the shares of MRTX in report with “Buy” rating. On Thursday, March 8 the stock of Mirati Therapeutics, Inc. (NASDAQ:MRTX) earned “Buy” rating by SunTrust.

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products.The firm is valued at $1.03 billion. The company's clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.Currently it has negative earnings. The Company’s clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: